Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Percardia
AddedMar 20, 2024
UpdatedJun 18, 2026
Percardia

Percardia

Acquired

Innovative device company treating coronary artery disease. Founded in 1998.

HQ
Merrimack, NH, US
Founded
1998
Overview
Compare
Fundraising
Employees

Percardia is a medical device company focused on developing innovative therapies for coronary artery disease. Its flagship product, the VSTENT myocardial implant, is a balloon-deployable stainless steel stent designed to improve heart health. Founded in 1998, Percardia is based in Merrimack, New Hampshire.

Percardia has made significant strides in the medical device industry, particularly in the treatment of coronary artery disease. The VSTENT has been recognized for its advanced design and effectiveness, contributing to better patient outcomes.

Percardia - Similar Companies

Novostent logo

Novostent

Phoenix Cardiac logo

Phoenix Cardiac

Ancora Heart logo

Ancora Heart

ancoraheart.com

Vascular Dynamics logo

Vascular Dynamics

Cardiac Dimensions logo

Cardiac Dimensions

Medlogics Device logo

Medlogics Device

Vaso logo

Vaso

CardioOptics logo

CardioOptics

Cordis logo

Cordis

cordis.com

MedNews logo

MedNews

Trireme Medical logo

Trireme Medical

VisCardia logo

VisCardia

viscardia.com

Cardio Flow logo

Cardio Flow

cardioflow.net

Viacor logo

Viacor

Cardiomems logo

Cardiomems

Percardia - Quick Facts

Who are Percardia's competitors?

Companies similar to Percardia include Novostent, Phoenix Cardiac, Ancora Heart and Vascular Dynamics.

When was Percardia founded?

Percardia was founded in 1998.

Where is Percardia's headquarters located?

Percardia's headquarters is located in Merrimack, NH, US.

When was Percardia's last funding round?

Percardia's most recent funding round was for $23.5M (USD) in November 2003.

How much has Percardia raised to-date?

As of Nov 7, 2003, Percardia has raised a total of $23.5M (USD).

Percardia - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Stents
Geographic Exposure
  • Americas
Revenue
  • Transactional
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified